Affiliations 

  • 1 State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 North Lishi Road, Beijing 100037, China zsfuwai@vip.163.com
  • 2 Medanta, The Medicity Hospital, Sector 38, Gurgaon, Haryana 122041, India
  • 3 Instituto de Cardiologia - Fundacion Cardioinfantil, Centro Internacional de Arritmias Calle 163 A #13B- 60, Bogota, Colombia
  • 4 Republican Scientific Practical Centre Cardiology, R. Luxembourg Str. 110, Minsk 220036, Belarus
  • 5 Institut Jantung Negara, 145 Jalan Tun Razak, Kuala Lumpur 50400, Malaysia
  • 6 National Heart Centre Singapore, 5 Hospital Avenue, Singapore 169609, Singapore
  • 7 West China Hospital, Sichuan University, No. 37 Guo Xue St., Chengdu 610041, China
  • 8 Cardiovascular Center, 5/F, National Taiwan University Hospital, No. 7, Chung Shan S. Rd, Zhong Zheng District, Taipei City 10002, Taiwan
  • 9 Medtronic, CRHF Clinical Research, 8200 Coral Sea Street NE, Mounds View, Minneapolis, MN 55112, USA
  • 10 Korea University Medical Center, A126-1 5th St. Anam-dong Sungbuk-ku, Seoul 136-705, Korea
Europace, 2015 Nov;17(11):1720-6.
PMID: 26037794 DOI: 10.1093/europace/euv103

Abstract

This study aims to demonstrate that primary prevention (PP) patients with one or more additional risk factors are at a similar risk of life-threatening ventricular arrhythmias when compared with secondary prevention (SP) patients, and would receive similar benefit from an implantable cardioverter defibrillator (ICD), or cardiac resynchronization therapy-defibrillator (CRT-D) implant. The study evaluates the benefits of therapy for high-risk patients in countries where defibrillation therapy for PP of SCA is underutilized.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.